Current management of atopic dermatitis and interruption of the atopic march - 29/08/11

Doi : 10.1016/j.jaci.2003.09.031

Mark Boguniewicz, MD ^a,^⁎,^{^{1
Dr Boguniewicz has received research support/grants from Novartis and Fujisawa, and has received a lecture honoraria from Novartis and Fujisawa.}}, Lawrence F Eichenfield, MD ^b,^{^{2
Dr. Eichenfield has received grants for clinical trial participation from Novartis and Fujisawa, and has received honoraria for lectures from Novartis and Fujisawa.}}, Thomas Hultsch, MD ^c,^d,^{^{3
Dr Hultsch is an employee of Novartis.}}
^a Division of Pediatric Allergy-Immunology, National Jewish Medical and Research Center and University of Colorado School of Medicine, Denver, Colo, USA
^b Department of Pediatric and Adolescent Dermatology, Children's Hospital and Health Center and University of California, San Diego, Calif, USA
^c Department of Dermatology, University of Mainz, Mainz, Germany
^d Novartis, East Hanover, NJ, USA

Reprint requests: Mark Boguniewicz, MD, Division of Pediatric Allergy-Immunology, National Jewish Medical and Research Center, 1400 Jackson St, J-310, Denver, CO 80206

Abstract

Treatment of atopic dermatitis requires a comprehensive approach that includes evaluation of potential triggers and education of the patient and family regarding proper avoidance measures. Hydration of the skin and maintenance of an intact skin barrier remain integral to proper management. Although topical corticosteroids have been a mainstay of anti-inflammatory therapy, the newer topical calcineurin inhibitors offer advantages for treatment of this chronic, relapsing disease. Studies aimed at defining optimal combination therapy and early intervention might change the treatment paradigm for atopic dermatitis.

Le texte complet de cet article est disponible en PDF.

Keywords : Atopic dermatitis, atopy, asthma, steroids, calcineurin inhibitors

Abbreviations : AD, EASI, FTU, IGA, NF-ATp, PUVA, SCORAD